OMICS-based personalized oncology: if it is worth doing, it is worth doing well!

Area of Science:

• Oncology
• Translational Research
• Biomarker Discovery

Background:

• Personalized medicine requires precise treatments tailored to individual patients.
• Tumor biomarker tests are crucial for achieving personalized medicine goals.
• Current translational research for tumor biomarker tests often lacks rigor and scientific methodology.

Purpose of the Study:

• To propose a standardized checklist for prospective clinical trials on tumor biomarker tests.
• To enhance the generation of high-level evidence demonstrating the clinical utility of tumor biomarker tests.
• To address the need for more rigorous research following the U.S. Institute of Medicine's roadmap for omics-based biomarker tests.

Main Methods:

• Review and synthesis of existing research methodologies in tumor biomarker testing.
• Development of a checklist of criteria for designing prospective clinical trials.
• Incorporation of principles from the U.S. Institute of Medicine's roadmap for omics-based biomarker development.

Main Results:

• A proposed checklist of criteria for investigators planning tumor biomarker clinical trials.
• Emphasis on generating high levels of evidence for clinical utility.
• Alignment with initiatives to increase the rigor of tumor biomarker research.

Conclusions:

• The proposed criteria will improve the quality of evidence for tumor biomarker test clinical utility.
• Implementing these criteria will enhance the perceived value of tumor biomarker research in clinical practice.
• Standardized approaches are essential for advancing personalized medicine through reliable biomarker tests.